Related Experiment Video
Updated: Jun 6, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Lenalidomide: an update on evidence from clinical trials
Meletios-Athanassios Dimopoulos1, Evangelos Terpos
1Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece. mdimop@med.uoa.gr
Blood Reviews
|December 4, 2010
Summary
Lenalidomide, an immunomodulatory drug, shows significant benefits in multiple myeloma (MM) treatment. Combining it with dexamethasone improves survival and progression-free survival (PFS) in both relapsed and newly diagnosed MM patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma (MM) is a hematologic malignancy.
- Lenalidomide is an immunomodulatory agent with dual antitumor and immune-modulating effects.
- Current treatment strategies aim to improve survival and prolong remission in MM patients.
Purpose of the Study:
- To evaluate the efficacy and safety of lenalidomide-based regimens in multiple myeloma.
- To compare lenalidomide plus dexamethasone with dexamethasone alone in relapsed/refractory MM.
- To assess lenalidomide plus low-dose dexamethasone versus standard high-dose dexamethasone in newly diagnosed MM.
Main Methods:
- Phase III clinical trials were conducted.
- Patients with relapsed/refractory MM and newly diagnosed MM were included.
- Treatment regimens involved lenalidomide in combination with dexamethasone.
Main Results:
- Lenalidomide plus dexamethasone improved response rates, time to progression, progression-free survival (PFS), and overall survival (OS) in relapsed/refractory MM.
- In newly diagnosed MM, lenalidomide plus low-dose dexamethasone prolonged survival compared to high-dose dexamethasone.
- Lenalidomide-based treatments are generally well-tolerated, with manageable adverse events like myelosuppression and thromboembolism.
Conclusions:
- Lenalidomide-based treatment is effective across various stages of multiple myeloma.
- Early initiation of lenalidomide therapy optimizes benefits, offering a new option for MM management.
- The combination is effective and tolerable in patients with renal impairment when doses are adjusted and monitored.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...